For the year ending 2025-12-31, HALO made $1,396,611K in revenue. $316,889K in net income. Net profit margin of 22.69%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 1,396,611 | |||
| Cost of sales | 228,774 | |||
| Amortization of intangibles | 76,662 | |||
| Research and development | 81,490 | |||
| Selling, general and administrative | 207,092 | |||
| Impairment of intangible asset | 48,700 | |||
| Acquired in-process research and development expense | 284,887 | |||
| Total operating expenses | 927,605 | |||
| Operating income | 469,006 | |||
| Investment and other income, net | 21,472 | |||
| Inducement expense related to convertible notes | 5,477 | |||
| Contingent liability fair value measurement gain | 0 | |||
| Interest expense | 18,126 | |||
| Income before income tax expense | 466,875 | |||
| Income tax expense | 149,986 | |||
| Net income | 316,889 | |||
| Basic (in shares) | 119,840,000 | |||
| Basic (usd per share) | 2.64 | |||
| Diluted (in shares) | 123,904,000 | |||
| Diluted (usd per share) | 2.56 | |||
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)